Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
Joint Authors
Gasbarrini, Antonio
Cammarota, G.
Milella, Michele
Carbone, Carmine
Piro, Geny
Di Noia, Vincenzo
D’Argento, Ettore
Vita, Emanuele
Ferrara, Miriam Grazia
Pilotto, Sara
Tortora, Giampaolo
Bria, Emilio
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-11-11
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Lung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in cancer treatment.
Immunotherapy is rapidly changing standard treatment schedule and outcomes for patients with advanced malignancies.
However, several ongoing studies are still attempting to elucidate the biomarkers that could predict treatment response as well as the new strategies to improve antitumor immune system response ameliorating immunotherapy efficacy.
The complex of bacteria, fungi, and other microorganisms, termed microbiota, that live on the epithelial barriers of the host, are involved in the initiation, progression, and dissemination of cancer.
The functional role of microbiota has attracted an accumulating attention recently.
Indeed, it has been demonstrated that commensal microorganisms are required for the maturation, education, and function of the immune system regulating the efficacy of immunotherapy in the anticancer response.
In this review, we discuss some of the major findings depicting bacteria as crucial gatekeeper for the immune response against tumor and their role as driver of immunotherapy efficacy in lung cancer with a special focus on the distinctive role of gut and lung microbiota in the efficacy of immunotherapy treatment.
American Psychological Association (APA)
Carbone, Carmine& Piro, Geny& Di Noia, Vincenzo& D’Argento, Ettore& Vita, Emanuele& Ferrara, Miriam Grazia…[et al.]. 2019. Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators of Inflammation،Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1193308
Modern Language Association (MLA)
Carbone, Carmine…[et al.]. Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators of Inflammation No. 2019 (2019), pp.1-10.
https://search.emarefa.net/detail/BIM-1193308
American Medical Association (AMA)
Carbone, Carmine& Piro, Geny& Di Noia, Vincenzo& D’Argento, Ettore& Vita, Emanuele& Ferrara, Miriam Grazia…[et al.]. Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators of Inflammation. 2019. Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1193308
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1193308